

PROXY

I/We, the undersigned, _____ (name of shareholder) with registered office at/residing at _____ (the "Principal"), being the holder of _____ registered shares of

d'Amico International Shipping S.A.

a *société anonyme* governed by the laws of the Grand Duchy of Luxembourg, registered with the Luxembourg Register of Commerce and Companies under number B 124790 and having its registered office at 25 C, boulevard Royal, L-2449 Luxembourg, Grand Duchy of Luxembourg (the "**Company**"), hereby constitute and appoint.....

.....or, in his/her absence, (i) the Chairman¹ of the meeting, or alternatively (ii) any of the following delegated representatives of the Company, *Maître* Remy Bonneau, lawyer, with professional address in the Grand Duchy of Luxembourg or *Maître* Eugenie Syx, lawyer, with professional address in the Grand Duchy of Luxembourg, or *Maître* Lucas Hieronimus, lawyer, with professional address in the Grand Duchy of Luxembourg, any other lawyer at Linklaters LLP, with registered office at Avenue John F. Kennedy 35, L-1855 Luxembourg (each an "**Agent**") as the Principal's true and lawful Agent for the purpose of representing the Principal at the annual general meeting of shareholders of the Company to be held at the registered office of the Company, on 29 April 2026 at 11:30 (CEST) Luxembourg time (the "**Meeting**"), with the following

AGENDA

- 1) Consideration of the management's reports on the statutory and consolidated annual accounts of the Company and of the reports of the Company's independent auditor ("réviseur d'entreprises agréé") on the consolidated annual accounts of the Company, on the statutory annual accounts of the Company and on the sustainability statement for the financial year ended on 31 December 2025;**

- 2) Consideration and approval of the Company's statutory annual accounts for the financial year ended on 31 December 2025;**

¹ Please note, for the purposes of assessing possible conflicts of interest, that the Chairman of the meeting may potentially be an employee, a member of the Board of Directors, a shareholder, an adviser or service provider of the Company.

- 3) Consideration and approval of the Company's consolidated annual accounts for the financial year ended on 31 December 2025;**
- 4) Approval of the allocation of results of the financial year ended on 31 December 2025 and payment of dividends in relation to the financial year ended on 31 December 2025;**
- 5) Discharge to the members of the Board of Directors in respect of the performance of their duties during the financial year ended on 31 December 2025;**
- 6) Approval of fees payable to the members of the Board of Directors for the financial year 2026;**
- 7) Renewal of the appointment of the independent auditor of the Company ("réviseur d'entreprises agréé") for a period ending at the Company's annual general meeting of shareholders called to approve the 2028 consolidated and statutory annual accounts of the Company;**
- 8) Consideration and advisory vote on the general remuneration policy for the financial year 2026 and on the remuneration report for the financial year ended on 31 December 2025.**

The Agent may represent the Principal at the Meeting or any adjourned meeting of the annual general meeting of shareholders convened for the purpose of resolving on the above agenda, waive any convening formalities or publications, vote on the Principal's behalf on any resolutions submitted to said meeting, sign any attendance list, minutes or any other documents and, in general, do whatever seems appropriate or useful, promising ratification.

The Agent is more in particular instructed to vote in the following manner on behalf of the Principal on the resolutions of the agenda of the Meeting:

- 1) Consideration of the management's reports on the statutory and consolidated annual accounts of the Company and of the reports of the Company's independent auditor ("réviseur d'entreprises agréé") on the consolidated annual accounts of the Company, on the statutory annual accounts of the Company and on the sustainability statement for the financial year ended on 31 December 2025.**

N/A

- 2) Consideration and approval of the Company's statutory annual accounts for the financial year ended on 31 December 2025.**

For

Against

Abstention

- 3) Consideration and approval of the Company's consolidated annual accounts for the financial year ended on 31 December 2025.

For

Against

Abstention

- 4) Approval of the proposal of the Board of Directors to allocate the statutory net profit for the financial year ending on 31 December 2025 amounting to US\$ 53,080,873 as follows:

Retained earnings as at 1 January 2025	USD	46,433,731
Results for the financial year 2025	USD	53,080,873
Other movements in retained earnings during 2025	USD	(35,033,950)
Retained earnings as at 31 December 2025	USD	64,178,203

Allocation to the legal reserve in 2026	USD	-
Share Premium as at 31 December 2025	USD	326,657,825.00
Amount distributable following allocation to legal reserve	USD	390,836,028.00
Interim Dividend resolved on 6 November 2025 and paid on 19 November 2025	USD	(15,941,715.00)
Proposed Annual Dividend 2025	USD	32,121,366.21

and - in accordance with the applicable Luxembourg law and the Company's articles of association – to approve the payment of a gross annual dividend of US\$ 0.27 (US\$ 0.2295 net, after deducting the maximum applicable withholding tax of 15%) per issued and outstanding share corresponding to a total distribution of approximately US\$ 32,121,366.21 to be paid out of the retained earnings to the Company's Shareholders (other than to the treasury shares held by the Company which, pursuant to the decision of the board of directors of the Company, shall not carry a dividend right).

For

Against

Abstention

5) Discharge to the members of the Board of Directors in respect of the performance of their duties during the financial year ended on 31 December 2025.

For

Against

Abstention

6) Approval of management fees payable to the members of the Board of Directors for the financial year 2026.

For

Against

Abstention

7) Approval of the renewal of the appointment of Moore Audit S.A., Luxembourg as independent auditor of the Company ("*réviseur d'entreprises agréé*") for a period ending at the Company's annual general meeting of shareholders called to approve the 2028 consolidated and statutory annual accounts of the Company.

For

Against

Abstention

8) Consideration and advisory vote on the general remuneration policy for the financial year 2026 and on the remuneration report for the financial year ended on 31 December 2025.

For

Against

Abstention

Please indicate with an "X" in the appropriate boxes how you wish the Agent to vote.

The Principal acknowledges that the Agent is to vote as instructed in respect of the resolutions specified above and that, if the appropriate boxes are not ticked for each of the above resolutions, the Agent will abstain on the resolutions in respect of which the boxes are not ticked and, unless instructed otherwise, on any other business (including amendments to resolutions) which may come before the Meeting.

The Principal acknowledges that if he completes and returns this proxy form this will not prevent Principal from attending in person and voting at the Meeting should the Principal subsequently decide to do so.

This proxy shall be sent by email to ABN AMRO via e-mail to corporate.broking@nl.abnamro.com **no later than 5 p.m. (CEST) Luxembourg time, of the 24th day of April 2026.**

As mentioned in the Convening Notice, upon provision of the Certificate of Holding and the Proxy Form, and subject to the Declaration of Intention to Participate being timely received by the Company, the Shareholder will receive Registration Certificate which will serve as an admission ticket for the Proxy Holder to the Meeting.

On the day of the Meeting date, the proxy holder is requested to produce to the Meeting in order to present it to the board of the Meeting: the Registration Certificate, as well as the original of the executed proxy if sent by e-mail, along with a copy of a valid ID document in order to identify the proxy holder.

Executed in _____ on _____ 2026.

By _____

Name of shareholder: _____

Represented by _____

Name of representative: _____

Title of representative: _____